.
Labor
Fund 3
Vesalius Biocapital III

This fund, launched in May 2017 and finally closed in May 2019, targets later-stage European life science companies in drug development, medtech, diagnostics and eHealth / mHealth.

€120 million of commitments secured

The fund secured over €120 million of commitments; final closing took place in May 2019.

Portfolio

News

News for Vesalius Biocapital Fund 3

CatalYm: Responses to Cancer
read more
Memo Therapeutics: Series C financing
read more
Scenic Biotech: Collaboration BMS
read more
.

xxnoxx_zaehler